EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

Resmetirom and semaglutide are recommended for treating non-cirrhotic MASH with fibrosis stages 2-3, with specific patient profiles guiding therapy choice.

• Why it matters: Effective management of MASH is crucial to prevent serious liver-related outcomes and cardiometabolic complications, yet optimal pharmacotherapy strategies remain under guidance.
• What they did: The guidance reviews the use of resmetirom and semaglutide, including patient selection, treatment initiation, monitoring, and discontinuation, based on non-invasive tests and individual risk factors.
• The result: Individualized therapy can be optimized by considering patient preferences and comorbidities, with ongoing studies assessing long-term benefits and safety in cirrhotic MASH.